IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v14y2016i5d10.1007_s40258-016-0256-z.html
   My bibliography  Save this article

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal

Author

Listed:
  • M. Reza Maleki-Yazdi

    (Women’s College Hospital, University of Toronto)

  • Mathieu Molimard

    (CHU and University of Bordeaux)

  • Dorothy L. Keininger

    (Primary Care Franchise, Novartis Pharma AG, Postfach)

  • Jean-Bernard Gruenberger

    (Primary Care Franchise, Novartis Pharma AG, Postfach)

  • Joao Carrasco

    (Health Economics and Outcomes Research, Novartis Farma–Produtos Farmacêuticos SA.)

  • Claudia Pitotti

    (Health Economics, Novartis Farma S.p.A.)

  • Elsa Sauvage

    (Strategy Pricing, Novartis Pharma S.A.S.)

  • Sara Chehab

    (Health Policy and Patient Access, Novartis Pharmaceuticals Canada Inc.)

  • David Price

    (University of Aberdeen)

Abstract

Objective The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who had a history of one or no exacerbations in the previous year, in Canada, France, Italy, and Portugal. Methods A patient-level simulation was developed to compare the costs and outcomes of IND/GLY versus SFC based on data from the LANTERN trial (NCT01709903). Monte-Carlo simulation methods were employed to follow individual patients over various time horizons. Population and efficacy inputs were derived from the LANTERN trial. Considering the payers’ perspective, only direct costs were included. Costs and health outcomes were discounted annually at 3.0 % for all countries. Unit costs were taken from publically available sources with all costs converted to euros (€). The cost base year was 2015. Deterministic and probabilistic sensitivity analyses were undertaken to test the robustness of the model results. Results IND/GLY was found to be the dominant (more effective and less costly) treatment option compared with SFC in all four countries. The use of IND/GLY was associated with mean total cost savings per patient over a lifetime of €6202, €1974, €1611, and €220 in Canada, France, Italy, and Portugal, respectively. Sensitivity analysis showed that exacerbation rates had the largest impact on incremental costs and quality-adjusted life-years (QALYs). The probability of IND/GLY being cost effective was estimated to be >95 % for thresholds above €5000/QALY. Conclusion In patients with moderate to severe COPD, IND/GLY is likely to be a cost-effective treatment alternative compared with SFC.

Suggested Citation

  • M. Reza Maleki-Yazdi & Mathieu Molimard & Dorothy L. Keininger & Jean-Bernard Gruenberger & Joao Carrasco & Claudia Pitotti & Elsa Sauvage & Sara Chehab & David Price, 2016. "Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination S," Applied Health Economics and Health Policy, Springer, vol. 14(5), pages 579-594, October.
    • Handle: RePEc:spr:aphecp:v:14:y:2016:i:5:d:10.1007_s40258-016-0256-z
    DOI: 10.1007/s40258-016-0256-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-016-0256-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-016-0256-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Yumi Asukai & Michael Baldwin & Tiago Fonseca & Alastair Gray & Laura Mungapen & David Price, 2013. "Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling," PharmacoEconomics, Springer, vol. 31(2), pages 151-161, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:14:y:2016:i:5:d:10.1007_s40258-016-0256-z. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.